AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder
Romain Marignier, Sean J Pittock, Friedemann Paul, Ho Jin Kim, Jeffrey L. Bennett, Brian G. Weinshenker, Dean M. Wingerchuk, Ari Green, Kazuo Fujihara, Gary Cutter, Orhan Aktaş, Hans‐Peter Hartung, Jörn Drappa, John N. Ratchford, Dewei She, Michael Smith, William A. Rees, Daniel Cimbora, Eliezer Katz, Bruce Cree
Topics & Concepts
Neuromyelitis opticaMedicineSerostatusSpectrum disorderInternal medicineMultiple sclerosisPlaceboRandomized controlled trialConfidence intervalPediatricsImmunologyPhysical therapyPathologyPsychiatryHuman immunodeficiency virus (HIV)Viral loadAlternative medicineMultiple Sclerosis Research StudiesVestibular and auditory disordersPeripheral Neuropathies and Disorders